Helix BioPharma (TSX:HBP) Long-Term Debt : C$0.00 Mil (As of Jul. 2024)

View and export this data going back to 1996. Start your Free Trial

What is Helix BioPharma Long-Term Debt?

Helix BioPharma's Long-Term Debt for the quarter that ended in Jul. 2024 was C$0.00 Mil.

Helix BioPharma Long-Term Debt Historical Data

The historical data trend for Helix BioPharma's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Helix BioPharma Long-Term Debt Chart

Helix BioPharma Annual Data

Trend

Jul15

Jul16

Jul17

Jul18

Jul19

Jul20

Jul21

Jul22

Jul23

Jul24

Long-Term Debt

Get a 7-Day Free Trial

1.58

Helix BioPharma Quarterly Data
	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24
Long-Term Debt	Get a 7-Day Free Trial															-	-	-	-	-

Helix BioPharma (TSX:HBP) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Helix BioPharma Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Helix BioPharma's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Helix BioPharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Helix BioPharma Corp (TSX:HBP) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

HBPCF:USA HBP0:Germany

Address

40 Temperance Street, Suite 2700, Bay Adelaide Centre - North Tower, Toronto, ON, CAN, M5H0B4

Website

https://www.helixbiopharma.com

Helix BioPharma Corp is a clinical-stage biopharmaceutical company. It is focused on cancer drug development. The company develops therapies in the field of immuno-oncology based on its proprietary technology mainly in the areas of cancer prevention and treatment. Its pipeline candidate is L-DOS47 for Tumor Defence Breaker is in clinical trials for pancreatic cancer.